Natera, Inc. (NASDAQ:NTRA) Shares Purchased by US Bancorp DE

US Bancorp DE lifted its stake in Natera, Inc. (NASDAQ:NTRAFree Report) by 31.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 17,372 shares of the medical research company’s stock after acquiring an additional 4,182 shares during the quarter. US Bancorp DE’s holdings in Natera were worth $1,088,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 0.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company’s stock worth $334,388,000 after acquiring an additional 67,102 shares during the last quarter. Kynam Capital Management LP increased its stake in Natera by 3.6% during the 3rd quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock worth $132,912,000 after buying an additional 103,668 shares during the period. RTW Investments LP increased its stake in Natera by 1.5% during the 3rd quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company’s stock worth $117,341,000 after buying an additional 40,000 shares during the period. Invesco Ltd. increased its stake in Natera by 52.0% during the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock worth $111,930,000 after buying an additional 865,404 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Natera by 7.1% during the 4th quarter. Principal Financial Group Inc. now owns 1,703,615 shares of the medical research company’s stock worth $106,714,000 after buying an additional 112,825 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Robert W. Baird upped their target price on shares of Natera from $99.00 to $117.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Jefferies Financial Group assumed coverage on shares of Natera in a research note on Monday. They set a “buy” rating and a $142.00 target price on the stock. Craig Hallum assumed coverage on shares of Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 target price on the stock. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. Finally, The Goldman Sachs Group increased their price objective on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.19.

Get Our Latest Analysis on NTRA

Natera Trading Up 1.7 %

Shares of Natera stock opened at $108.31 on Tuesday. The company has a fifty day simple moving average of $97.58 and a 200-day simple moving average of $78.50. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $110.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12.

Natera (NASDAQ:NTRAGet Free Report) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business had revenue of $367.70 million during the quarter, compared to analysts’ expectations of $316.31 million. During the same quarter in the prior year, the business posted ($1.23) EPS. The company’s revenue for the quarter was up 52.1% on a year-over-year basis. As a group, equities analysts expect that Natera, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Daniel Rabinowitz sold 787 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total transaction of $71,916.06. Following the completion of the sale, the insider now owns 205,552 shares in the company, valued at approximately $18,783,341.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Daniel Rabinowitz sold 787 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total transaction of $71,916.06. Following the completion of the sale, the insider now owns 205,552 shares in the company, valued at approximately $18,783,341.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 447 shares of the stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $90.22, for a total transaction of $40,328.34. Following the sale, the insider now owns 347,731 shares of the company’s stock, valued at approximately $31,372,290.82. The disclosure for this sale can be found here. Insiders sold a total of 263,106 shares of company stock worth $24,521,761 in the last 90 days. Company insiders own 7.60% of the company’s stock.

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAFree Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.